Who makes AC-076 for s.c. administration?

AC-076 for s.c. administration is developed by Viatris Innovation GmbH.

What development phase is AC-076 for s.c. administration in?

AC-076 for s.c. administration is in Phase 1.

Last reviewed 2026-04-23 · How we verify

AC-076 for s.c. administration

Viatris Innovation GmbH · Phase 1 active Small molecule

At a glance

Generic name	AC-076 for s.c. administration
Sponsor	Viatris Innovation GmbH
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AC-076 for s.c. administration CI brief — competitive landscape report
AC-076 for s.c. administration updates RSS · CI watch RSS
Viatris Innovation GmbH portfolio CI